新加坡的产前皮质类固醇:临床和科学评估。

IF 1.7 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Singapore medical journal Pub Date : 2024-09-01 Epub Date: 2022-10-06 DOI:10.4103/SINGAPOREMEDJ.SMJ-2022-014
Arundhati Gosavi, Zubair Amin, Sean William David Carter, Mahesh Arjandas Choolani, Erin Lesley Fee, Mark Amir Milad, Alan Hall Jobe, Matthew Warren Kemp
{"title":"新加坡的产前皮质类固醇:临床和科学评估。","authors":"Arundhati Gosavi, Zubair Amin, Sean William David Carter, Mahesh Arjandas Choolani, Erin Lesley Fee, Mark Amir Milad, Alan Hall Jobe, Matthew Warren Kemp","doi":"10.4103/SINGAPOREMEDJ.SMJ-2022-014","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Preterm birth (PTB; delivery prior to 37 weeks' gestation) is the leading cause of early childhood death in Singapore today. Approximately 9% of Singaporean babies are born preterm; the PTB rate is likely to increase given the increased use of assisted reproduction technologies, changes in the incidence of gestational diabetes/high body mass index and the ageing maternal population. Antenatal administration of dexamethasone phosphate is a key component of the obstetric management of Singaporean women who are at risk of imminent preterm labour. Dexamethasone improves preterm outcomes by crossing the placenta to functionally mature the fetal lung. The dexamethasone regimen used in Singapore today affords a very high maternofetal drug exposure over a brief period of time. Drawing on clinical and experimental data, we reviewed the pharmacokinetic profile and pharmacodynamic effects of dexamethasone treatment regimen in Singapore, with a view to creating a development pipeline for optimising this critically important antenatal therapy.</p>","PeriodicalId":21752,"journal":{"name":"Singapore medical journal","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antenatal corticosteroids in Singapore: a clinical and scientific assessment.\",\"authors\":\"Arundhati Gosavi, Zubair Amin, Sean William David Carter, Mahesh Arjandas Choolani, Erin Lesley Fee, Mark Amir Milad, Alan Hall Jobe, Matthew Warren Kemp\",\"doi\":\"10.4103/SINGAPOREMEDJ.SMJ-2022-014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>Preterm birth (PTB; delivery prior to 37 weeks' gestation) is the leading cause of early childhood death in Singapore today. Approximately 9% of Singaporean babies are born preterm; the PTB rate is likely to increase given the increased use of assisted reproduction technologies, changes in the incidence of gestational diabetes/high body mass index and the ageing maternal population. Antenatal administration of dexamethasone phosphate is a key component of the obstetric management of Singaporean women who are at risk of imminent preterm labour. Dexamethasone improves preterm outcomes by crossing the placenta to functionally mature the fetal lung. The dexamethasone regimen used in Singapore today affords a very high maternofetal drug exposure over a brief period of time. Drawing on clinical and experimental data, we reviewed the pharmacokinetic profile and pharmacodynamic effects of dexamethasone treatment regimen in Singapore, with a view to creating a development pipeline for optimising this critically important antenatal therapy.</p>\",\"PeriodicalId\":21752,\"journal\":{\"name\":\"Singapore medical journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Singapore medical journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/SINGAPOREMEDJ.SMJ-2022-014\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/10/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Singapore medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/SINGAPOREMEDJ.SMJ-2022-014","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

早产(PTB;妊娠 37 周前分娩)是当今新加坡幼儿死亡的主要原因。约有 9% 的新加坡婴儿是早产儿;随着辅助生殖技术的使用增加、妊娠糖尿病/高体重指数发病率的变化以及孕产妇人口的老龄化,早产率可能会上升。产前服用地塞米松磷酸盐是对有即将早产风险的新加坡产妇进行产科管理的一个重要组成部分。地塞米松可通过胎盘使胎儿肺功能成熟,从而改善早产预后。目前,新加坡使用的地塞米松方案可在短时间内使母体和胎儿接触大量药物。根据临床和实验数据,我们回顾了新加坡地塞米松治疗方案的药代动力学特征和药效学效应,以期为优化这种极其重要的产前疗法建立一个开发管道。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antenatal corticosteroids in Singapore: a clinical and scientific assessment.

Abstract: Preterm birth (PTB; delivery prior to 37 weeks' gestation) is the leading cause of early childhood death in Singapore today. Approximately 9% of Singaporean babies are born preterm; the PTB rate is likely to increase given the increased use of assisted reproduction technologies, changes in the incidence of gestational diabetes/high body mass index and the ageing maternal population. Antenatal administration of dexamethasone phosphate is a key component of the obstetric management of Singaporean women who are at risk of imminent preterm labour. Dexamethasone improves preterm outcomes by crossing the placenta to functionally mature the fetal lung. The dexamethasone regimen used in Singapore today affords a very high maternofetal drug exposure over a brief period of time. Drawing on clinical and experimental data, we reviewed the pharmacokinetic profile and pharmacodynamic effects of dexamethasone treatment regimen in Singapore, with a view to creating a development pipeline for optimising this critically important antenatal therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Singapore medical journal
Singapore medical journal MEDICINE, GENERAL & INTERNAL-
CiteScore
3.40
自引率
3.70%
发文量
149
审稿时长
3-6 weeks
期刊介绍: The Singapore Medical Journal (SMJ) is the monthly publication of Singapore Medical Association (SMA). The Journal aims to advance medical practice and clinical research by publishing high-quality articles that add to the clinical knowledge of physicians in Singapore and worldwide. SMJ is a general medical journal that focuses on all aspects of human health. The Journal publishes commissioned reviews, commentaries and editorials, original research, a small number of outstanding case reports, continuing medical education articles (ECG Series, Clinics in Diagnostic Imaging, Pictorial Essays, Practice Integration & Life-long Learning [PILL] Series), and short communications in the form of letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信